Abstract: The present invention relates to a method for producing high levels of functional recombinant proteins in adenovirus-transformed mammalian cells by incubating cells capable of producing recombinant proteins at a temperature range between about 38 degrees centigrade and about 39 degrees centigrade. The method allows for higher levels of expression of total protein in some cell lines and higher levels of functional protein in other cell lines.

Abstract: The present invention relates to a DNA molecule containing intron sequences and encoding a human protein which is, depending on the site of action, called Bile Salt-Stimulated Lipase (BSSL) or Carboxyl Ester Lipase (CEL). The DNA molecule is advantageously used in the production of recombinant human BSSL/CEL, preferably by means of production in transgenic non-human mammals. The recombinant human BSSL/CEL can be used as a constituent of infant formulas used for feeding infants as a substitute for human milk, or in the manufacture of medicaments against e.g. fat malabsorption, cystic fibrosis and chronic pancreatitis.

Abstract: This invention relates to lipase containing pharmaceutical compositions comprising a microbial, 1, 3-position specific, crystalline lipase and to methods for treatment or prophylaxis of lipase deficiency in mammals.

Abstract: Full-length cDNA clones have been isolated encoding purified augmenter of liver regeneration (ALR) polypeptides prepared from the cytosol of livers from weanling rats and from humans. The full-length clone from the rat is a 1226 bp cDNA containing an 81 bp 5'-untranslated region, a 594 bp coding region and a 551 bp 3'-untranslated region. The coding region encodes three proteins with estimated molecular weights of 15,081, 20,193 and 22,835. The full-length clone from the human consists of a 727 bp cDNA containing a 4 bp 5'-untranslated region, a 615 bp coding region and a 108 bp 3'-untranslated region, including the termination codon TAG and the poly (A) region. The 615 bp coding region encodes four proteins, human ALR-V1, ALR-V2, ALR-V3 and ALR, having estimated molecular weights of 23,448, 20,834, 20,703 and 15,028, respectively.

Abstract: Disclosed is a process for producing an aromatic amino acid selected from the group consisting of L-tryptophan, L-tyrosine and L-phenylalanine which comprises culturing in a medium a mutant strain of the genus Corynebacterium or Brevibacterium, being capable of producing the aromatic amino acid and also having higher transketolase activity than that of a parent strain thereof until the aromatic amino acid is produced and accumulated in the culture, and recovering the aromatic amino acid therefrom.

Abstract: A method for producing protein in a cell-free system uses cell-free extract required for protein production, extracted from a biological cell. According to the present invention, a wide range of proteins can be produced economically and efficiently even in a semi-continuous operation mode, by regenerating energy source, increasing operation time of the reactor with porous solid material and using selective protein isolating means having high specific affinity to a desired protein. Thus, problems appearing in the living cell (in vivo) system due to the absence of post-translational processing can be avoided and the total production amount can be greatly increased due to prolonged operation time of the reactor and increased protein productivity.

Abstract: A xylanase from Aureobasidium pullulans having a high specific activity is provided as well as a signal protein for controlling excretion into cell culture medium of proteins to which it is attached. DNA encoding these proteins is also provided.

Abstract: A binary assay identifies agents that inhibit sterol .DELTA.14 reductase involved in ergosterol biosynthesis. In the primary screen, sterol .DELTA.14 reductase inhibition by a test sample is assayed by adding the test sample to a culture of Neurospora crassa having an erg-3 mutation and also to a culture of a strain having an erg-1 mutation, comparing the extent of growth inhibition after incubation in the two cultures, and identifying as positives those samples that show growth inhibition in the erg-3 culture exceeding that in the erg-1 culture. In the secondary screen, samples that test positive in the primary screen are reassayed by adding the test sample to a culture of a Saccharomyces cerevisiae strain into which has been introduced multiple copies of a gene encoding sterol .DELTA.14 reductase and also to a strain of S.

Abstract: Nucleic acid sequences, particularly DNA sequences, coding for all or part of a squalene synthetase, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of a squalene synthetase, and methods for producing these polypeptide molecules.

Abstract: The present invention relates to a bile acid sulfate sulfatase gene coding for the amino acid sequence as shown in FIG. 4 and the gene derived from bacteria which belongs to genus Pseudomonas testosteroni, or a bile acid sulfate sulfatase gene as shown in FIG. 3, a plasmid containing the gene, a method for producing a bile acid sulfate sulfatase, and a bile acid sulfate sulfatase.

Abstract: The sequence, molecular structure and expression of a cDNA clone, denoted D4, of human and murine origin, preferentially expressed in hematopoietic cells is described herein. The human cDNA clone has been expressed in bacteria and the predicted 24 Kd protein purified. The protein has been used in studies of its biochemical function. As predicted on the basis of sequence, D4 can function as a GDP-dissociation inhibitor of at least several small GTP-binding proteins (CDC42 and rac). The D4 protein was used to generate a polyclonal antibody specific for the protein. The human cDNA was used to obtain several full length murine genomic clones. A clone has been analyzed and sequenced to use for the construction of a gene-targeting vector to produce animals deficient in D4 through disruption of the gene by homologous recombination. These animals can then be used as models for fundamental and applied research on the GTP-binding proteins.

Abstract: A method is described for diagnosing rheumatoid arthritis by providing a recombinant antigen (RAMA) and detecting rheumatoid arthritis-associated IgM antibodies against the RAMA antigen in patient sera. The RAMA antigen comprises SEQ ID NO:3 and peptides substantially homologous thereto. A purified and isolated DNA encoding the RAMA antigen and a transformed host containing the DNA are also disclosed.

Abstract: This application relates to modified blood coagulation factors, DNA sequences coding for such modified factors and a process for their production.

Abstract: A method of purifying protein farnesyltransferase (Ftase) uses recombinant technology and yeast host cells. Yeast farnesyltransferase purified by the method is useful in confirming specificity and kinetics of potential protein farnesyltransferase inhibitors. These inhibitors are useful for chemotherapy directed against cancers related to ras oncogenes.

Abstract: A new human gene termed DCC is disclosed. Methods and kits are provided for assessing mutations of the DCC gene in human tissues and body samples. Insertion, deletion, and point mutations in DCC are observed in human tumor cells. Normal tissues express DCC while most colorectal cancers do not. Loss of wild-type DCC genes is associated with neoplastic progression and a diminished life expectancy.

Abstract: An isolated nucleic acid sequence is described having at least one siderophore biosynthetic gene from Bacillus subtilis encoding enzymes homologous to enterobactin enzymes EntA, EntB, EntC, EntE, and combinations thereof. Vectors containing the isolated nucleic acid sequence, host cells transformed wth the isolated nucleic acid sequence, and a method for identifying compounds having antibiotic activity against microorganisms with an enterobactin-type siderophore are also described.

Abstract: Novel plasmids comprising genes which code for the alcohol dehydrogenase and pyruvate decarboxylase are have been transformed with genes coding for alcohol dehydrogenase and pyruvate. By virtue of their transformation with these genes, the recombinant hosts are capable of producing significant amounts of ethanol as a fermentation product. Also disclosed are methods for increasing the growth of recombinant hosts and methods for reducing the accumulation of undesirable metabolic products in the growth medium of these hosts. Also disclosed are recombinant host capable of producing significant amounts of ethanol as a fermentation product of oligosaccharides and plasmids comprising genes encoding polysaccharases, in addition to the genes described above which code for the alcohol dehydrogenase and pyruvate decarboxylase. Further, methods are described for producing ethanol from oligomeric feedstock using the recombinant hosts described above.

Abstract: The in vitro cloning of a gene for human placental ribonuclease inhibitor may be obtained by recombinant DNA technology. The method described obtains the gene encoding human placental ribonuclease inhibitor, the expression of that product in a host cell, and the refolding and purifying of the product. A vector which includes an encoded DNA gene sequence coding for human placental ribonuclease inhibitor is also described, as well as a host that is compatible with and contains the vector. The gene sequence of the human placental ribonuclease inhibitor is also presented.

Abstract: Full-length cDNA clones have been isolated encoding purified augmenter of liver regeneration (ALR) polypeptides prepared from the cytosol of livers from human and from weanling rats. The 0.5 kb human ALR cDNA includes a 33 bp 5'-untranslated region, a 375 bp coding region and a 107 bp 3'-untranslated region. The cDNA encodes a protein consisting of 125 amino acids. The molecular weight of human ALR calculated from the cDNA was 15,028. A comparison of the sequences for the human ALR with those of the rat ALR shows 71% homology at the nucleotide level and 86% homology at the amino acid level. The most obvious immediate clinical use for the augmenter of liver regeneration is in the treatment of hepatic failure.

Abstract: A purified DNA molecule encoding a glycoprotease from Pasteurella haemolytica is disclosed. The DNA comprises a sequence of approximately 975 base pairs coding for a glycoprotease having a molecular weight of approximately 35.2 kD. The glycoprotease is specific for cleaving O-glycosylated carbohydrate portions from O-glycoproteins. The glycoprotease has a major cleavage site in glycophorin A between Arg31 and Asp32.